Expert Perspectives on CDK4/6 Inhibitors in HR-Positive, HER2-Negative Breast Cancer

Register now for this complimentary, live 1-hour CME-certified meeting featuring expert discussion of cases and the latest data on leveraging CDK4/6 inhibitors in hormone receptor–positive, HER2-negative breast cancer.

Afterward, use CCO’s online Interactive Decision Support Tool for metastatic breast cancer (coming soon) to gain expert advice customized to your own challenging cases and download the associated slideset based on the content of the live meetings.

Agenda

  • Background on hormone receptor–positive, HER2-negative advanced breast cancer
  • The growing role of CDK4/6 inhibitors in treating hormone receptor–positive advanced breast cancer
    • Critical review of key clinical trials data: palbociclib, ribociclib, abemaciclib
    • Practical application in the clinic: CDK4/6 inhibition and endocrine partner
  • Clinical management of potential toxicities and drug interactions related to CDK4/6 inhibitors in breast cancer
  • Emerging data, ongoing clinical trials, and future directions
    • Acquired resistance to CDK4/6 inhibitors
    • Moving CDK4/6 inhibition into earlier settings
    • Biomarkers for CDK4/6 response

Events

Date / Time
Event Details
9/27/2018
12:00 PM
1/31/2019
4:00 PM

Faculty

Program Chair
Mohammad Jahanzeb, MD, FACP

Professor of Clinical Medicine, Hematology-Oncology
Medical Director, USylvester Deerfield Campus
Associate Center Director for Community Outreach
Sylvester Comprehensive Cancer Center
University of Miami, Miller School of Medicine
Deerfield Beach, Florida

Program Chair
Ruth O'Regan, MD

Professor
Division of Hematology/Oncology
Department of Medicine
UW School of Medicine and Public Health
UW Carbone Cancer Center
University of Wisconsin–Madison
Madison, Wisconsin

Faculty
Sara Hurvitz, MD

Associate Professor of Medicine
Director, Breast Oncology Program
Division of Hematology-Oncology
Department of Medicine
David Geffen School of Medicine at UCLA
Los Angeles, California

Faculty
Virginia Kaklamani, MD, DSc

Professor, Department of Medicine
University of Texas Health Science Center San Antonio
San Antonio, Texas

Faculty
Kevin Kalinsky, MD, MS

Assistant Professor of Medicine
Division of Medical Oncology
Department of Medicine
Columbia University Medical Center
New York, New York

Faculty
Reshma Mahtani, DO

Associate Professor of Medicine
Department of Hematology/Oncology
Breast Medical Oncologist
Sylvester Cancer Center
University of Miami
Deerfield Beach, Florida

Faculty
Kathy Miller, MD

Professor of Medicine
Ballve’ Lantero Scholar in Oncology
Co-Director, IU Simon Cancer Center Breast Cancer Program
Indiana University Melvin and Bren Simon Cancer Center
Indianapolis, Indiana

Faculty
Anne O'Dea, MD

Assistant Professor
Breast Oncologist
Director
, Breast Cancer Survivorship
Division of Medical Oncology
Department of Medicine
University of Kansas Cancer Center
Westwood, Kansas

Faculty
Ruta Rao, MD

Associate Professor of Medicine
Division of Hematology and Oncology
Rush University Medical Center
Chicago, Illinois

Faculty
Jasgit Sachdev, MD

Director, Breast-Gynecologic Cancers Early Clinical Trials
Clinical Associate Professor, Clinical Translational Research Division
HonorHealth Research Institute/TGEN
Scottsdale, Arizona

Faculty
Tiffany Traina, MD

Associate Attending Physician
Clinical Director, Breast Medicine Service
Section Head, Triple Negative Breast Cancer Research Program
Breast Medicine Service
Department of Medicine
Memorial Sloan Kettering Cancer Center
Assistant Professor of Medicine, WCMC
New York, New York

Faculty
Kari Wisinski, MD

Associate Professor of Medicine
Co-Leader
, UWCCC Breast Cancer Oriented Team
University of Wisconsin Carbone Cancer Center
Associate Professor
Division of Hematology and Medical Oncology
Department of Medicine
University of Wisconsin Hospital and Clinics
Madison, Wisconsin

CME

Goal Statement
The goal of this activity is to improve participants’ performance in using CDK4/6 inhibitors to improve outcomes for patients with advanced hormone receptor–positive, HER2-negative breast cancer.

Target Audience 
This program is intended for medical oncologists, the multidisciplinary team, and associated healthcare providers who care for patients with breast cancer.

Learning Objectives 

  • Discuss the rationale for targeting CDK4/6 in breast cancer
  • Evaluate available clinical data on abemaciclib, palbociclib, and ribociclib and their applications to current treatment algorithms for patients with de novo or recurrent metastatic hormone receptor–positive, HER2-negative breast cancer
  • Describe current therapeutic strategies and ongoing clinical trials of CDK4/6 inhibitors for hormone receptor–positive, HER2-negative breast cancer
  • Explain similarities and differences among the CDK4/6 inhibitors
  • Summarize mechanisms of acquired resistance to CDK4/6 inhibitors and current treatment options after disease progression on CDK4/6 inhibitor–based therapy
  • Identify potential biomarkers of sensitivity to CDK4/6 inhibitors
  • Manage toxicities specific to CDK4/6 inhibitors

Accreditation

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Clinical Care Options, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest 
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.